- Home
- EMD vs PHAR Comparison
EMD vs PHAR Comparison
Compare EMD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMD
- PHAR
- Stock Information
- Founded
- EMD 2003
- PHAR 1988
- Country
- EMD United States
- PHAR Netherlands
- Employees
- EMD N/A
- PHAR N/A
- Industry
- EMD Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- EMD Finance
- PHAR Health Care
- Exchange
- EMD Nasdaq
- PHAR Nasdaq
- Market Cap
- EMD 527.7M
- PHAR 587.5M
- IPO Year
- EMD N/A
- PHAR N/A
- Fundamental
- Price
- EMD $9.12
- PHAR N/A
- Analyst Decision
- EMD
- PHAR Strong Buy
- Analyst Count
- EMD 0
- PHAR 3
- Target Price
- EMD N/A
- PHAR $30.00
- AVG Volume (30 Days)
- EMD 248.5K
- PHAR 4.6K
- Earning Date
- EMD 01-01-0001
- PHAR 05-08-2025
- Dividend Yield
- EMD 10.25%
- PHAR N/A
- EPS Growth
- EMD N/A
- PHAR N/A
- EPS
- EMD N/A
- PHAR N/A
- Revenue
- EMD N/A
- PHAR $297,200,000.00
- Revenue This Year
- EMD N/A
- PHAR $8.26
- Revenue Next Year
- EMD N/A
- PHAR $9.73
- P/E Ratio
- EMD N/A
- PHAR N/A
- Revenue Growth
- EMD N/A
- PHAR 21.15
- 52 Week Low
- EMD $7.85
- PHAR $6.65
- 52 Week High
- EMD $9.55
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- EMD 41.71
- PHAR 45.53
- Support Level
- EMD $8.56
- PHAR $7.79
- Resistance Level
- EMD $9.09
- PHAR $8.51
- Average True Range (ATR)
- EMD 0.25
- PHAR 0.47
- MACD
- EMD -0.02
- PHAR 0.01
- Stochastic Oscillator
- EMD 41.18
- PHAR 49.08
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management investment company. Its primary investment objective is to seek high current income and the secondary objective is to seek capital appreciation.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.